General information
Immutep GmbH
Deutscher Platz 5a
04103 Leipzig, Saxony
Germany
Contact person: Christian Rudolf, Office & IT Manager
Company main phone: +49 (341) 23100372
Website: https://www.immutep.com/
Source of foundation: | Subsidiary |
Name of foundation source: | Prima BioMed Ltd, Australia |
Corporate description / mission:
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology. The company's products include a T cell immunostimulatory factor (APC activator) for cancer chemo-immunotherapy and a therapeutic antibody for immune response modulation in cancer.
State of ownership: Subsidiary
Headquarters: No
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Antibodies
- Immunotherapy
- Proteins
- Other
|
Primary therapeutic areas: |
- Infectious and parasitic diseases / infectiology / parasitology
- Neoplasms / cancer / oncology
|
Business model: |
- Manufacturer
- R&D
- Subsidiary
|
Customer segments: |
- Other
- Hospitals
- Large biotech & big pharma
- Small biotech
|
Summary Products / Services / Technologies
Description of products:
IMP701, a blocking anti-LAG-3 antibody for cancer
IMP761, an agonist antibody of LAG-3, etc.
Technology used:
LAG-3 Technology